Iridium [IRMD] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Iridium Corporation

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Iridium Corporation wins in 7 metrics, Abbott Laboratories wins in 12 metrics, with 1 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Iridium Corporation Abbott Laboratories Better
P/E Ratio (TTM) 50.74 25.97 Abbott Laboratories
Price-to-Book Ratio 12.00 3.09 Abbott Laboratories
Debt-to-Equity Ratio 0.00 26.79 Tie
PEG Ratio 2.08 -1.41 Iridium Corporation
EV/EBITDA 39.69 13.74 Abbott Laboratories
Profit Margin (TTM) 26.82% 13.90% Iridium Corporation
Operating Margin (TTM) 31.26% 16.50% Iridium Corporation
EBITDA Margin (TTM) 31.26% 16.50% Iridium Corporation
Return on Equity 24.78% 12.36% Iridium Corporation
Return on Assets (TTM) 15.78% 7.52% Iridium Corporation
Free Cash Flow (TTM) $16.53M $7.40B Abbott Laboratories
Dividend Yield 1.38% 1.97% Abbott Laboratories
1-Year Return 56.63% -35.92% Iridium Corporation
Price-to-Sales Ratio (TTM) 13.54 3.57 Abbott Laboratories
Enterprise Value $1.08B $166.96B Abbott Laboratories
EV/Revenue Ratio 12.93 3.70 Abbott Laboratories
Gross Profit Margin (TTM) 75.06% N/A N/A
Revenue per Share (TTM) $7 $26 Abbott Laboratories
Earnings per Share (Diluted) $1.75 $3.57 Abbott Laboratories
Beta (Stock Volatility) 1.12 0.78 Abbott Laboratories
Short % of Float 6.16% 1.53% Abbott Laboratories

Iridium Corporation vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

IRMD
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Iridium Corporation1.40%-0.78%7.30%-12.63%-2.21%-4.59%
Abbott Laboratories0.02%1.53%-0.63%-23.43%-30.57%-29.95%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Iridium Corporation56.63%85.97%221.38%377.91%930.23%930.23%
Abbott Laboratories-35.92%-17.85%-21.68%118.48%249.25%313.73%

Performance & Financial Health Analysis: Iridium Corporation vs Abbott Laboratories

MetricIRMDABT
Market Information
Market Cap i$1.14B$160.70B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i86,65713,495,583
90 Day Avg. Volume i91,37612,934,461
Last Close$91.12$86.99
52 Week Range$55.11 - $107.90$81.97 - $139.06
% from 52W High-15.55%-37.44%
All-Time High$107.90 (Feb 10, 2026)$142.60 (Dec 27, 2021)
% from All-Time High-15.55%-39.00%
Growth Metrics
Quarterly Revenue Growth0.17%0.08%
Quarterly Earnings Growth0.25%-0.19%
Financial Health
Profit Margin (TTM) i0.27%0.14%
Operating Margin (TTM) i0.31%0.17%
Return on Equity (TTM) i0.25%0.12%
Debt to Equity (MRQ) i0.0026.79
Cash & Liquidity
Book Value per Share (MRQ)$7.40$30.02
Cash per Share (MRQ)$4.00$5.14
Operating Cash Flow (TTM) i$24.95M$10.80B
Levered Free Cash Flow (TTM) i$6.64M$13.77B
Dividends
Last 12-Month Dividend Yield i1.38%1.97%
Last 12-Month Dividend i$1.38$2.40

Valuation & Enterprise Metrics Analysis: Iridium Corporation vs Abbott Laboratories

MetricIRMD (Apr 24, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i50.7425.97
Forward P/E i38.2815.29
PEG Ratio i2.08-1.41
Price to Sales (TTM) i13.543.57
Price to Book (MRQ) i12.003.09
Market Capitalization
Market Capitalization i$1.14B$160.70B
Enterprise Value i$1.08B$166.96B
Enterprise Value Metrics
Enterprise to Revenue i12.933.70
Enterprise to EBITDA i39.6913.74
Risk & Other Metrics
Beta i1.120.78
Book Value per Share (MRQ) i$7.40$30.02

Financial Statements Comparison: Iridium Corporation vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricIRMD (2025)ABT (2025)
Revenue/Sales i83.81M44.33B
Cost of Goods Sold i19.49M19.32B
COGS % of Revenue i23.3%43.6%
Gross Profit i64.32M25.01B
Gross Margin i76.7%56.4%
Research & Development i2.98M2.94B
Operating Income (EBIT) i26.15M8.05B
Operating Margin i31.2%18.2%
EBITDA i27.11M12.03B
EBITDA Margin i32.3%27.1%
Pre-Tax Income i28.36M8.47B
Pre-Tax Income % of Revenue i33.8%19.1%
Income Tax i5.88M1.94B
Income Tax % of Revenue i7.0%4.4%
Net Income (Profit) i22.48M6.52B
Profit Margin i26.8%14.7%

Balance Sheet & Liquidity Metrics

MetricIRMD (2025)ABT (2025)
Cash & Equivalents i51.16M8.52B
Total Current Assets i81.20M26.00B
Total Current Assets % of Revenue i96.9%58.6%
Total Current Liabilities i10.18M16.50B
Total Current Liabilities % of Revenue i12.1%37.2%
Long-Term Debt i010.83B
Long-Term Debt % of Revenue i0.0%24.4%
Total Shareholders Equity i94.62M52.77B
Retained Earnings i64.23M49.78B
Retained Earnings % of Revenue i76.6%112.3%
Property, Plant & Equipment i017.57B

Cash Flow Statement Comparison

MetricIRMD (2025)ABT (2025)
Operating Cash Flow i26.24M10.80B
Operating Cash Flow % of Revenue i31.3%24.4%
Capital Expenditures i-7.77M-2.17B
Free Cash Flow i16.53M7.40B
FCF Margin i19.7%16.7%
Debt Repayment iN/A-1.50B
Common Stock Repurchase iN/A-893.00M

Short Interest & Institutional Ownership Analysis

MetricIRMDABT
Shares Short i499,38023.83M
Short Ratio i6.281.93
Short % of Float i6.16%1.53%
Shares Outstanding i12.78M1.74B
Float Shares i8.26M1.73B
% Held by Insiders i36.61%0.54%
% Held by Institutions i59.70%82.23%
% Held by Public i3.69%17.23%

Dividend Analysis & Yield Comparison: Iridium Corporation vs Abbott Laboratories

MetricIRMDABT
Last 12-Month Dividend i$1.38$2.40
Last 12-Month Dividend Yield i1.38%1.97%
3-Year Avg Annual Dividend i$0.82$2.24
3-Year Avg Dividend Yield i0.41%0.50%
3-Year Total Dividends i$2.46$6.72
Ex-Dividend DateFeb 23, 2026Jan 15, 2026